EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Hepatitis B virus reactivation in oncology patients: Mechanisms, risk stratification, and international guidelines

Hanna Gruchot, Karolina Jastrzębska, Anna Kuźnar, Robert Wiraszka

Przeglad Epidemiologiczny · 05.05.2026

DOI: 10.32394/pe/221169 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Przeglad Epidemiologiczny, online erschienen am 05.05.2026. Verfasst von Hanna Gruchot und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B virus (HBV) infection remains a major challenge in oncology because systemic anticancer treatment may trigger HBV reactivation (HBVr). This narrative review summarizes current knowledge on the incidence, mechanisms, risk factors and prevention of HBVr in patients receiving chemotherapy or other immunosuppressive regimens. HBVr occurs in approximately 20-50% of HBV-infected patients treated with cytostatics, with the highest risk in hematological malignancies and during anti-CD20 antibody therapy or allogeneic hematopoietic stem cell transplantation. Clinically, HBVr ranges from asymptomatic alanine aminotransferase flares to fulminant liver failure, causes treatment disruption in up to two-thirds of affected patients, and is associated with mortality of about 5%, rising to nearly 30% in hepatocellular carcinoma. The pathophysiology of HBVr involves persistence of intranuclear cccDNA, loss of T- and B-cell immune surveillance and direct pro-replicative effects of selected drugs, including strong glucocorticosteroids, TNF-α antagonists, anthracyclines, tyrosine kinase inhibitors and CAR-T-cell therapies. We compare key recommendations from European guidance (EASL) and Polish national recommendations regarding screening strategies, HBVr risk stratification, and indications for nucleos(t)ide analogue prophylaxis. Effective prevention of HBV reactivation starts with pre-treatment screening, followed by antiviral prophylaxis with high resistance barrier agents or structured virological surveillance in carefully selected clinical scenarios with feasible, reliable monitoring.

Zitieren

APA

Gruchot, H., Jastrzębska, K., Kuźnar, A., & Wiraszka, R. (2026). Hepatitis B virus reactivation in oncology patients: Mechanisms, risk stratification, and international guidelines. Przeglad Epidemiologiczny. https://doi.org/10.32394/pe/221169

Vancouver

Gruchot H, Jastrzębska K, Kuźnar A, Wiraszka R. Hepatitis B virus reactivation in oncology patients: Mechanisms, risk stratification, and international guidelines. Przeglad Epidemiologiczny. 2026. doi:10.32394/pe/221169

BibTeX
@article{Gruchot2026,
  author = {Gruchot, Hanna and Jastrzębska, Karolina and Kuźnar, Anna and Wiraszka, Robert},
  title = {Hepatitis B virus reactivation in oncology patients: Mechanisms, risk stratification, and international guidelines},
  journal = {Przeglad Epidemiologiczny},
  year = {2026},
  doi = {10.32394/pe/221169}
}
Kostenlos starten →